Skip to content

Net margin at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
16.8%+5.1pp
ALN
Alnylam PharmaceuticalsALNY
11.7%+8.0pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-125.9%-54.5pp
Arrowhead Research logo
Arrowhead ResearchARWR
-48.4%+240pp
United Therapeutics logo
United TherapeuticsUTHR
40.6%+0.2pp
Biogen logo
BiogenBIIB
14.3%-0.8pp

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Calculated from PTC Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: PTC Therapeutics’s 10-Q, filed November 4, 2025, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTC Therapeutics's net margin?
PTC Therapeutics (PTCT) reported net margin of 42.3% in Q3 2025.
How has PTC Therapeutics's net margin changed year-over-year?
PTC Therapeutics's net margin increased by 184.0% year-over-year, from -50.3% to 42.3%.
What is the long-term trend for PTC Therapeutics's net margin?
Over 4 years (2020 to 2024), PTC Therapeutics's net margin has grown at a -20.9% compound annual growth rate (CAGR), from -115.1% to -45%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.